Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study
{{output}}
Aim: To determine the smallest worthwhile difference (SWD) for lecanemab, a disease-modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit-harm trade-off method. ... ...
